AstraZeneca, Daiichi Sankyo’s drug shows promise in breast cancer patients in trial

Alexis Juanita

Roland Magnusson AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) said on Thursday that their medicine datopotamab deruxtecan (Dato-DXd) showed durable efficacy in patients with a type of breast cancer in an early stage study. The two-part, phase 1 trial, dubbed TROPION-PanTumor01, is evaluating datopotamab deruxtecan in patients with advanced solid […]